Real-World Treatment Patterns in Patients with Metastatic Castration-Sensitive Prostate Cancer in Japan: A Retrospective Health Administrative Data Analysis.

ABSTRACT:

Introduction

Since 2020, several androgen receptor signaling inhibitors (ARSIs) have been approved for use among patients with metastatic castration-sensitive prostate cancer (mCSPC) in Japan. To evaluate how these approvals may have changed the mCSPC treatment landscape in Japan, we analyzed treatment patterns and time to treatment discontinuation (TTD) since 2020 in patients with mCSPC.

Methods

This retrospective cohort study utilized data from the Medical Data Vision health administrative database between May 2020 and March 2024. Study endpoints were patient characteristics at baseline, first-line, and subsequent-line treatment patterns; TTD of first-line therapies; and TTD of first-line ARSIs. Patient characteristics were analyzed descriptively. Hazard ratios (HRs) for T

SUBMITTER: Kawai T 

PROVIDER: S-EPMC12858562 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature